Company Products Research Collaborators Regulatory Investor Relations Contact Us  


A Unique Business Model:
Network Accesses Resources, Capacity & Infrastructure without Major Investment

With the lack of products in the pharma research pipelines and the high cost of development, we at Nuovo Biologics believe our business model is an alternative solution to the current pharma paradigm.  We are decentralizing the process by developing partnerships and collaborations that fulfill the continuum of services necessary for new product development.  In an effort to be cost effective, promote quality, and enhance creativity and innovation, Nuovo Biologics is creating a strong network foundation of partners and collaborators.  We have extended participation by product to both private and academic researchers, clinical practitioners, para-professionals, contract manufacturers, market and distribution experts and other industry stakeholders.

University of Florida School of Public Health Emerging Pathogens Institute (EPI)

Nuovo Biologics has entered into an agreement with the College of Public Health at the University of Florida.  Dr. Lednicky is an internationally known virologist.  He has already conducted in vitro testing of our drug against canine distemper and we have planned for a series of in vitro tests that will include human influenza viruses as well as a number of animal viruses.

East Tennessee Research Center
Craig R, Reinemeyer, D.V.M, PhD

The East Tennessee Research Center (ETRC), operated by Dr. Craig Reinemeyer, is a CRO (Contract Research Organization) focusing on non-consumable animal clinical research. Dr. Reinemeyer and his staff are acting as consultants to support our clinical trial protocol development.  Nuovo Biologics is working with ETRC to complete our Target Animal Studies (TAS) with canines and equines.

Dr. Reinemeyer is a native of Ohio, and graduated cum laude from the Ohio State University College of Veterinary Medicine in 1976.  After 5 years in mixed animal practice in Kent, Ohio, Dr. Reinemeyer returned to OSU to pursue a PhD in veterinary parasitology.  His graduate studies focused on the epidemiology and control of nematode parasites of grazing animals, and his dissertation topic addressed specific aspects of the biology of equine parasites.  Dr. Reinemeyer joined the faculty of the University of Tennessee College of Veterinary Medicine in 1984 and taught veterinary parasitology there for 14 years.  He is a member of numerous professional organizations, and served as the President of the American Association of Veterinary Parasitologists from 2003 to 2004.

Dr. Reinemeyer left academia in 1998 to found East Tennessee Clinical Research (ETCR) with a major emphasis on clinical studies with horses.  Safety, efficacy, pharmacokinetic and bioequivalence studies are also conducted with dogs, cats, cattle, and other domestic livestock.  Dr. Reinemeyer has authored over 70 peer-reviewed articles and book chapters, and has delivered over 200 papers at scientific meetings and continuing education conferences.  Pivotal clinical studies conducted by Dr. Reinemeyer have contributed to the approval of one dozen New Animal Drug Applications (NADAs) and four Amended NADAs.

Rood & Riddle Equine Hospital
Stephen M. Reed, DVM, Dipl. ACVIM, Rood & Riddle Equine Hospital

Dr. Steve Reed of the Rood & Riddle Equine Hospital is collaborating with Nuovo Biologics to support clinical equine virus disease research.  Dr. Steve Reed is managing our clinical equine studies primarily aimed at equine herpes virus disease(s) and influenza, as well as studying the pharmacokinetics of PVX in equines.

Dr. Reed, a prominent equine internist and neurological disease specialist is a Professor Emeritus at Ohio State University.

Community Veterinary Hospital
Lester Mandelker, DVM, Community Veterinary Hospital

Dr. Lester Mandelker, is a prominent small animal veterinarian and proprietor of the Community Veterinary Hospital who has been in private practice since 1972.  A graduate of Michigan State University for both his undergraduate and veterinary degrees, he will assist Nuovo in preparing protocols and treatment procedures for small non-consumable animals.  The Community Veterinary Hospital, in Largo, Florida, is an AAHA Certified Hospital and Dr. Mandelker maintains active memberships in AVMA, FVMA, AAHA, FVMA, ABVP and the FAAVPT.

Over the last several decades Dr. Mandelker has maintained a high degree of peer respect and acknowledgement.  He was selected among the nation’s top veterinarians in 2006 & 2007 by the Consumer’s Research Council of America and was Chairman of the Examination Committee of the American Board of Veterinary Practitioners from 1990 to 1992.

Since 1986, Dr. Mandelker has been a Diplomat of The American Board of Veterinary Practitioners and is certified in Canine and Feline Medicine.  His specialty interest is Pharmacology, Nutraceuticals and Antioxidants.  Dr. Mandelker is also a Fellow of the American Academy of Pharmacology and Therapeutics (FAAVPT).

Dr. Mandelker has published over 175 scientific articles on pharmacology, medicine and nutraceuticals in journals such as: AVMA journal, VM/SAC, Veterinary Forum and The Veterinary Clinics of North America.

Dr. Mandelker has done extensive work in pharmacology and first introduced various human pharmacological agents to veterinary medicine.  He continues his active interest in animal pharmacology as a Pharmacology Consultant for Veterinary Forum, the Veterinary Information Network and is in demand as a speaker on Veterinary Pharmacology.

Auburn University School of Veterinary Medicine
Dr. Bruce Smith, VMD, PhD, Director of Auburn University Research Initiative in Cancer and Scientist in the Scott Richey Research Center, College of Veterinary Medicine
Dr. R. Curt Bird, PhD, Professor of Molecular Biology and Cancer Genetics, College of Veterinary Medicine
Dr. Annette Smith, DVM, Oncologist, College of Veterinary Medicine

The Auburn University College of Veterinary Medicine, under a collaborative research agreement, will study MMX as an anti-cancer drug with antiviral properties.  Scientists with the Auburn University Research Initiative in Cancer at the College of Veterinary Medicine will be working with Nuovo Biologics to examine the anti-tumor properties of MMX.  These studies will look at the drug from the perspective of its interactions with cells, as well as in clinical trials in dogs with malignant melanoma, a form of skin cancer.  Preliminary studies have shown that the drug appears to be safe, with no side effects, and is active against a wide variety of viruses.

“This agreement exemplifies how Auburn University scientists, working with biotech and pharmaceutical industries, can provide expertise to move exciting new discoveries from the laboratory into the clinic,” said AURIC director Dr. Bruce Smith.

The Auburn University Research Initiative in Cancer, or AURIC, embodies the “One Medicine” concept which links human, animal and environmental health, and where discoveries in one species advance health in all species.

Working with Dr. Smith will be Doctors Curt Bird and Annette Smith.

University of Pittsburgh School of Medicine
Robert Hendricks, PhD, Vice-Chair for Research in the Department of Ophthalmology and
Visual Sciences Research Center, University of Pittsburgh School of Medicine

Dr. Robert Hendricks is the Joseph F. Novak Professor and Vice-Chair for Research in the Department of Ophthalmology at the University of Pittsburgh School of Medicine.  We are collaborating with Dr. Hendricks to explore the use of PVX to treat herpes corneal keratitis.  His team has developed a mouse model for this disease indication and we plan to use this model to analyze PVX’s effectiveness against herpes corneal keratitis in this model.